浆细胞定向治疗在单克隆丙种球蛋白病相关硬化性黏液水肿中的应用
这项法国多中心回顾性研究纳入33例MG相关硬化性黏液水肿患者,分析临床与治疗特征及皮肤转录组。结果显示HDIVig对非重症有效,来那度胺/硼替佐米联合地塞米松和HDIVig改善重症,DNS急诊联合治疗使4/5患者神经症状完全缓解。
要点
- HDIVig单用或联合激素在非重症患者中临床完全缓解达13/31例。
- 来那度胺和/或硼替佐米联合地塞米松及HDIVig可显著改善重症病例。
- DNS急诊采用血浆置换、HDIVig和大剂量激素联合治疗,5例中4例神经症状完全缓解。
核心结论
- 浆细胞定向治疗(来那度胺和/或硼替佐米联合地塞米松及HDIVig)可显著改善重症MG相关硬化性黏液水肿。
- HDIVig单用或联合激素对非重症病例有效,临床完全缓解13/31例。
- DNS急诊联合血浆置换、HDIVig和大剂量激素可使4/5患者神经症状完全缓解。
研究设计与样本
- 法国多中心回顾性研究,纳入33例MG相关硬化性黏液水肿患者。
- 采用转录组学方法分析皮肤分子特征,并对6例皮肤样本行定量RT-PCR分析。
主要发现
- 皮肤症状包括丘疹性皮疹(100%)、硬皮病样特征(91%)和狮面(39%)。
- MG均为IgG同型,以λ轻链为主(73%);4/33例(12%)诊断相关血液恶性肿瘤。
- 常见系统并发症为腕管综合征(33%)、关节痛(25%)和皮肤神经综合征(DNS)(18%)。
- 1例黏液性心脏病患者死于急性心力衰竭。
- 6例皮肤样本中促纤维化通路(TGF-β和胶原-1)水平显著高于健康皮肤。
关键数值与推荐
- 非重症病例HDIVig单用或联合激素,临床完全缓解13/31例。
- 重症病例(HDIVig难治或伴中枢神经/心脏受累)使用来那度胺和/或硼替佐米联合地塞米松及HDIVig。
- DNS急诊采用血浆置换、HDIVig和大剂量皮质激素联合治疗,4/5例神经症状完全缓解。
临床怎么用
- 非重症MG相关硬化性黏液水肿可选用HDIVig单用或联合激素。
- 重症或HDIVig难治及伴中枢神经/心脏受累者,可考虑来那度胺和/或硼替佐米联合地塞米松及HDIVig。
- DNS急诊应联合血浆置换、HDIVig和大剂量皮质激素。
局限性
- 为回顾性研究,样本量33例。
- 皮肤转录组分析仅基于6例样本。
- 需前瞻性研究靶向浆细胞克隆和/或纤维化通路以指导长期管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Scleromyxedema is a rare skin and systemic mucinosis that is usually associated with monoclonal gammopathy (MG). In this French multicenter retrospective study of 33 patients, we investigated the clinical and therapeutic features of MG-associated scleromyxedema. Skin molecular signatures were analyzed using a transcriptomic approach. Skin symptoms included papular eruptions (100%), sclerodermoid features (91%), and leonine facies (39%). MG involved an immunoglobulin G isotype in all patients, with a predominant λ light chain (73%). Associated hematologic malignancies were diagnosed in 4 of 33 patients (12%) (smoldering myeloma, n = 2; chronic lymphoid leukemia, n = 1; and refractory cytopenia with multilineage dysplasia, n = 1). Carpal tunnel syndrome (33%), arthralgia (25%), and dermato-neuro syndrome (DNS) (18%) were the most common systemic complications. One patient with mucinous cardiopathy died of acute heart failure. High-dose IV immunoglobulin (HDIVig), alone or in combination with steroids, appeared to be quite effective in nonsevere cases (clinical complete response achieved in 13/31 patients). Plasma cell-directed therapies using lenalidomide and/or bortezomib with dexamethasone and HDIVig led to a significant improvement in severe cases (HDIVig refractory or cases with central nervous system or cardiac involvement). The emergency treatment of DNS with combined plasmapheresis, HDIVig, and high-dose corticosteroids induced the complete remission of neurological symptoms in 4 of 5 patients. Quantitative reverse-transcriptase polymerase chain reaction analysis of 6 scleromyxedema skin samples showed significantly higher profibrotic pathway levels (transforming growth factor β and collagen-1) than in healthy skin. Prospective studies targeting plasma cell clones and/or fibrotic pathways are warranted for long-term scleromyxedema management.
引用
- Mahévas T, Arnulf B, Bouaziz JD, et al. Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema. Blood. 2020. PMID: 32027747. doi:10.1182/blood.2019002300
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。